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Abstract 
 
This paper examines the potential health impact of genetically modified rice with a high folate content, i.e. folate 
biofortified rice, as an alternative tool to tackle folate deficiency in Shanxi Province. This poor Chinese region, with 33 
million inhabitants, is currently characterized by suboptimal folate intake levels, partly due to the low intake of folic 
acid supplements. Furthermore, Shanxi Province has one of the world’s highest reported prevalence rates of neural-tube 
defects (NTDs), which is the main adverse health outcome of folate deficiency. By using the Disability-Adjusted Life 
Years (DALY) approach, the introduction of folate biofortified rice in Shanxi Province is evaluated in terms of 
“healthy” years saved. Currently, NTDs attributable to folate deficiency in Shanxi Province are responsible for an 
annual loss between 67 195 and 114 232 years of “healthy” life. Under the assumption that folate biofortification in 
Shanxi Province results in an average daily folate intake of 637.4 µg, which protects women to have a baby with an 
NTD caused by folate deficiency, each year 24 830 and 93 569 DALYs can be saved in the low-low and high-high 
biofortification scenario, respectively. Our findings demonstrate that folate biofortification of rice can alleviate the 
burden of folate deficiency and the number of NTDs in Shanxi Province. Further studies are needed to assess and 
compare the cost-effectiveness of this and other interventions to reduce folate deficiency, such as folic acid fortification 
or supplementation. 
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Introduction 
 
Together with the main micronutrient deficiencies (Vitamin A, iron and zinc), folate deficiency or 
the suboptimal intake of folates remains a serious threat to the health of populations worldwide, in 
particular for children and pregnant woman. The main adverse health outcomes of folate deficiency 
are neural-tube defects (NTDs), i.e. the most important birth defect in the world (Christianson et al., 
2006). There is a clear relationship between maternal folate deficiency and the risk of having a baby 
with an NTD (Molloy and Scott, 2001; MRC Vitamin Study Research Group, 1991). Adequate 
periconceptional use of folic acid supplements significantly reduces this risk (Lumley et al., 2001). 
Because the use of folic acid pills is not well established in poor regions, folate biofortification, 
improving the micronutrient content of staple food crops, can be considered as a valuable 
alternative for pharmaceutical folic acid supplementation (Storozhenko et al., 2007). 
Shanxi Province, a coal mining region in the North of China, has one of the highest reported 
prevalence rates of NTDs in the world, with more than 100 out of 10 000 births suffering from an 
NTD (Gu et al., 2007; Li et al., 2006). This high incidence is correlated with low awareness and use 
of folic acid pills (Li et al., 2007; Ren et al., 2006) and suboptimal dietary folate intake levels of 
women of childbearing age (Ren et al., 2007; Zhang et al., 2008). This makes Shanxi Province an 
excellent region to investigate the health impact of folate biofortification.  
Although wheat is the main staple crop in Shanxi Province, this paper aims to evaluate the health 
impact of the introduction of folate biofortified rice in this region. So far, rice with a high folate 
content is the most advanced folate biofortified staple crop (Blancquaert et al., 2008; McIntosh et 
al., 2008). By metabolic engineering, Storozhenko et al. (2007) obtained different transgenic lines 
with a folate content ranging from 350 to 1 700 µg per 100 g of raw polished grains, which is 20 to 
100 times higher than the initial folate level of rice. Due to this high folate content of conventional 
rice, biofortification of the world’s most widely consumed staple crop is expected to have a large 
impact on public health, even in regions where rice is less consumed, such as Shanxi Province.  
By applying the Disability-Adjusted Life Years (DALY) approach (Murray and Lopez, 1996), the 
health benefits of folate biofortified rice in Shanxi Province are quantified in terms of the number of 
“healthy” life years saved. During the last decade a lot of efforts have been made to analyze the 
health impact of different biofortified crops on the burden of the main micronutrient deficiencies 
(Horton, 2006; Meenakshi et al., 2007; Stein et al., 2005). Recently, De Steur et al. (2010a) 
evaluated the introduction of folate biofortified rice in China. This paper builds further on their 
findings and focuses on the potential introduction of folate biofortified rice in Shanxi Province, i.e. 
the most problematic region in terms of NTD prevalence. 
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As folate enriched rice is not yet available on the market, this study should be considered as an ex-
ante analysis of the potential health impact of the introduction of folate biofortified rice on the 
burden of folate deficiency in a particular high risk region of Northern China. While women of 
childbearing age are considered as the target group of folate biofortified rice consumption, 
newborns are the ones who will benefit from their mothers’ biofortified diet. 
 
 
Materials and methods 
 
Mainly two analyses are inherent in the Disability-Adjusted Life Years framework as a means to 
calculate the health benefits of biofortified crops: the estimation of the current burden of the disease 
and the assessment of the potential reduction of this burden by biofortification. When applied to 
folate biofortified rice, the current burden of folate deficiency is estimated (1), which enables to 
assess the potential reduction of this burden resulting from folate biofortification of rice, i.e. the 
health impact (2). 
In the following subsections the use of the DALY framework and the data collection are described 
for each of these analyses. With respect to the theoretical background of applying the DALY 
approach to micronutrient deficiency and folate deficiency, special reference is made to Stein et al. 
(2005) and De Steur et al. (2010a), respectively. Therefore, the focus here lies on the data collection 
to measure the impact of folate enriched rice on folate deficiency in Shanxi Province. Although 
folate deficiency also results in other functional outcomes, such as megaloblastic anemia, only 
NTDs are covered in this research. The main reason is the lack of evidence of the contribution of 
folate deficiency to its different health outcomes. Thus, the ‘burden of folate deficiency’ refers to 
the negative health outcomes of the disease, i.e. NTDs. The latter is split up into three types, 
according to the malformation of the NTD. While anencephaly and encephalocele result in a 
malformed skull and brain, spina bifida is characterized by malformations in the spine (Molloy and 
Scott, 2001). 
 
Estimation of the burden of folate deficiency: the DALY formula 
 
Based on the DALY formula (Stein et al., 2005; Zimmermann and Qaim, 2004), the burden of a 
disease can be calculated in terms of the number of DALYs lost due to the mortality (“Years of Life 
Lost”, YLL) or morbidity (“Years Lived with Disability”, YLD) caused by the disease. The general 
DALY formula is expressed as follows:  
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- Tj: the total number of people in target group j, 
- Mj: the mortality rate associated with the deficiency in target group j, 
- Lj: the average remaining life expectancy for target group j, 
- Iij: the incidence rate of functional outcome i in target group j, 
- Dij: the disability weight for functional outcome i in target group j,   
- dij: the duration of functional outcome i in target group j, and  
- r: the discount rate for future life years.  
With respect to the DALY approach to measure the burden of folate deficiency, the target groups of 
the DALY formula refer to fatal or non-fatal births, and the functional outcomes are the different 
NTD types, caused by folate deficiency. Mortality refers to abortions and stillbirths, while 
morbidity mainly consists of live births suffering from two NTD types, spina bifida or 
encephalocele. Because infants born with anencephaly always die before or shortly after birth, this 
type is covered in the mortality statistics (Access Economics, 2006; Mathers et al., 1999).  
Table 1 summarizes the required data related to NTDs in Shanxi Province. The indicator 
definitions, calculation methods and sources on which these data rely are presented. Based on the 
population and the birth rate for Shanxi Province (Shanxi Province Statistical Bureau, 2007), it is 
possible to define the total births (live births and stillbirths) and the composition of NTDs according 
to morbidity and mortality. The data about NTD related figures and the input parameters of the 
DALY formula are further described below. 
 
Table 1 All neural-tube defects in Shanxi Province, indicator definition, calculation method and source. 
 
   Numbers for   
Shanxi  
Indicator definition/ 
Calculation method Source 
Total population 34 379 272 persons in 2006 (Shanxi Province Statistical Bureau, 2007) 
Birth rate           11.48 per 1000 population in 2006 (Shanxi Province Statistical Bureau, 2007) 
Births      394 674 BR*Total population/1000  
NTD prevalence rate         138.70 per 10 000 births  (Li et al., 2006) 
Total NTDs           5474 PR*Births/10 000  
1. NTD Live births           2194 40.09 % of NTDs (Li et al., 2006) 
a. Spina bifida            1605 73.14 % of NTD live births  (Berry et al., 1999; Gu et al., 2007; Li et al., 2006; Liu et al., 2007) 
b. Encephalocele             589 26.86 % of NTD live births (Berry et al., 1999; Gu et al., 2007; Li et al., 2006; Liu et al., 2007) 
2. NTD Stillbirths           1583 28.91 % of NTDs (Li et al., 2006) 
3. NTD Abortions           1697 31.00 % of NTDs (Li et al., 2006) 
NTD Morbidity           2195 1a + 1b  
NTD Mortality           3280 2 + 3  
BR, birth rate; NTD, neural tube defects; PR, prevalence rate of neural-tube defects 
 
First, the prevalence rate of NTDs in Shanxi Province is determined. Various authors examined the 
prevalence of NTDs in this region. Due to different data collection systems or different periods of 
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analysis, the prevalence rates in these studies differ significantly. Expressed per 10 000 births, the 
following rates are found in order of appearance: 105.5 in 1987 (Xiao, 1989), 149.0 in 1997 (Moore 
C et al., 1997), 138.7 in 2003 (Li et al., 2006) and 199.38 in 2002-2004 (Gu et al., 2007). As the 
latter prevalence rate only refers to two rural counties in the Lvliang mountain area of Shanxi 
Province, which partly explains its high rate, the NTD rate of Li et al. (2006) is selected because it 
is the most recent and it is in line with previous findings. As this prevalence rate refers to the 
number of NTDs within a time period, this rate is used as an approximate incidence rate.  
Second, the share of the three NTD types in the total number of NTD live births is based on 
findings from two country-wide Chinese (Berry et al., 1999; Liu et al., 2007) and two Shanxi 
studies (Gu et al., 2007; Li et al., 2006). As anencephaly is a part of NTD mortality, only the 
average prevalence of spina bifida and encephalocele are considered, based on a share between 
respectively 47.5-59.3 % and 7.5-34.4 % of all NTDs. These figures are in line with studies in the 
U.S. (Feuchtbaum et al., 1999), Canada (De Wals et al., 2007; Gucciardi et al., 2002) and Ireland 
(FSAI, 2006). 
Third, the mortality findings of the Shanxi study of Li et al. (2006) are adopted to the total number 
of NTDs, with 31 % and 28.91 % of all NTDs considered as abortions and stillbirths, respectively. 
Together, live births and stillbirths account for 69 % of NTDs. 
The NTD figures above refer to NTDs caused by folate deficiency as well as other causes, such as 
genetic and environmental factors (FSAI, 2006). Because this paper analyses the health impact of 
folate biofortification, only the NTDs that are attributable to folate deficiency are included in the 
DALY framework. To gather scientific evidence of the contribution of folate deficiency as a cause 
of NTDs, literature is reviewed on the relationship between maternal folic acid supplementation 
during the periconceptional period and the risk of having a baby with an NTD. While a few authors 
attempt to retrieve the non-linear association between folate intake and reduction of NTD incidence 
(Daly et al., 1997; Moore et al., 2003), most of the studies analyzed the effect of a daily folate 
intake of 400 µg (Lumley et al., 2001; Molloy and Scott, 2001). This dose is also advised by the 
WHO (2006) and the United States Public Health Service (USFDA, 1996). 
If women consume this recommended amount of folates, between 50 to 70 % of all cases of NTDs 
in the world can be prevented (Daly et al., 1997; Lumley et al., 2001; Molloy and Scott, 2001). 
According to a study in Northern China (Berry et al., 1999), the number of NTDs caused by folate 
deficiency is even higher (85 %). Thus, under the assumption that folate deficiency refers to a daily 
folate intake below 400 µg, 50 % to 85 % of all NTDs are considered to be attributable to folate 
deficiency in Shanxi Province. The general contribution levels  (50% and 70%) and the higher 
percentage (85 %) are chosen as the three reference points to define the number of NTDs 
attributable to folate deficiency.  
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Table 2 presents the total number of NTDs caused by folate deficiency, split up into two non-fatal 
(morbidity) and two fatal (mortality) functional outcomes. According to the highest contribution 
scenario, around 4653 NTDs are attributable to folate deficiency in Shanxi province. Almost 60 % 
of these NTDs are characterized by a fatal outcome. 
 
Table 2 All NTDs and NTDs attributable to folate deficiency in Shanxi Province, low, medium and high contribution 
scenario 
Functional outcome 
All NTDs 
(see Table 1) 
Contribution of folate deficiency to NTDs  % of total 
NTDs                Lowa            Mediumb Highc 
Morbidity      
Spina bifida 1 605 802 1 124 1 364 29.3 
Encephalocele    589    295 412 501 10.8 
Total 2 194 1 097 1 536 1 865 40.1 
Mortality      
Stillbirths 1 583 792 1 108 1 345 28.9 
Abortions 1 697 848 1 188 1 443 31.0  
Total 3 280 1 640 2 296 2 788 59.9  
Total 5 474 2 737 3 832 4 653   100.00 
a Low: 50 % of NTDs attributable to folate deficiency 
b Medium: 70 % of NTDs attributable to folate deficiency 
c High: 85 % of NTDs attributable to folate deficiency 
 
With respect to the DALY formula, the number of NTDs for each non-fatal and fatal functional 
outcome is considered as the combined input parameter TjIij and TjMj respectively. Besides these 
parameters, the DALY formula requires additional information to measure the current burden of 
folate deficiency, i.e. the number of DALYs lost under the status quo. Table 3 gives an overview of 
the main input parameters of the DALY formula. 
 
Table 3 Input parameters of the DALY formula, related to Shanxi Province  
Functional  
outcome 
TjIij TjMj    
Lowa Mediumb Highc Lowa  Mediumb Highc Lj = dij Dij r 
Morbidity          
Spina bifida  802 1 124 1 364 NA NA NA 73.11 yrs 0.593 
3 % 
Encephalocele      295        412 501 NA NA NA 73.11 yrs 0.520 
Mortality          
Stillbirths NA NA NA 792 1 108 1 345 73.11 yrs 1.0 
3 % 
Abortions NA NA NA 848 1 188 1 443 73.11 yrs 1.0 
NA, not applicable  
a Low: 50 % of NTDs attributable to folate deficiency 
b Medium: 70 % of NTDs attributable to folate deficiency 
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c High: 85 % of NTDs attributable to folate deficiency 
 
First, the input parameters regarding incidence (TjIij) and mortality rates (TjMj) within each target 
group are based on the number of NTDs caused by folate deficiency, as shown in Table 2. Second, 
the average remaining life expectancy (Lj) refers to the average life expectancy at birth in Shanxi 
Province, 73.11 years (Shanxi Province Statistical Bureau, 2007). Third, disability weights (Dij) for 
morbidity are described in the Global Burden of Disease (GBD) study (Murray and Lopez, 1996) 
and a more recent study in Australia (Mathers et al., 1999). Disability weights ranges from 0 (‘no 
disability’) to 1 (‘death’) according to the level of “severity” or “disability”. With respect to the 
non-fatal NTDs, the severity of encephalocele and spina bifida are more or less equal. The fourth 
input parameter, the duration of NTD morbidity (dij), is assumed to be permanent, by which dij 
equals the average life expectancy at birth. Fifth, the discount rate for future life years (r) amounts 3 
percent, similar to previous health impact studies (Stein et al., 2005; Zimmermann and Qaim, 
2004). 
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Factors influencing the health impact of folate biofortification  
 
The framework to assess the NTD related health benefits of folate biofortified rice is based upon 
previous literature (Qaim et al., 2006; Zimmermann and Qaim, 2004) and consists of the parameters 
that influence the number of DALYs lost under the “with” hypothesis, i.e. when folate biofortified 
rice is consumed (Figure 1). 
 
 
Figure 1 Framework to assess the health impact of introducing folate biofortified rice 
Source: De Steur et al. (2010a) 
 
As figure 1 illustrates, the health impact of folate biofortified rice depends primarily on 
biofortification characteristics (efficacy) and consumer characteristics (coverage). 
Efficacy is determined by the level of enhancement of folates in rice, potential folate losses after 
rice processing and its bioavailability. Compared with the initial folate content of rice, 8 µg per 100 
g (US Department of Agriculture Agricultural Research Service, 2009), folate biofortification of 
rice resulted in different transgenic lines with a folate content between 350 and 1700 µg per 100 g 
of raw polished grains (Storozhenko et al., 2007). The calculations in this study are based on a 
folate content of 1200 µg per 100g raw polished rice. Processing of rice, i.e. cooking, will retain 
approximately 50 % of the total folate content (Storozhenko et al., 2007). The degree of 
bioavailability depends on the source of folate. While folic acid in biofortified food is 85 % 
bioavailable and folic acid supplements are around 100 % bioavailable, natural folate in food has 
been shown to be only 50 % bioavailable (Bailey, 2004; FSAI, 2006). Although research is 
necessary to evaluate the exact bioavailability of folate biofortified rice, the theoretical 
bioavailability of natural folate (50 %) is taken into account. Based on the efficacy parameters, the 
folate intake of biofortified rice amounts 300 µg per 100 g rice. 
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The coverage rate refers to consumers’ acceptance of and accessibility to farmers in favor of folate 
enriched rice. The acceptance rate of rice with high folate content in Shanxi Province is based on an 
earlier study (De Steur et al., 2010b) where 55.4 % of all female rice consumers are willing to 
accept folate biofortified rice,  32.3 % react indifferent and 12·3 % are reluctant. Regarding Shanxi 
farmers the acceptance rate is 66.7 %, while 26.7 % of the farmers are indifferent. Based on these 
figures, a low and high coverage rate are defined. The low coverage rate (36.95 %) consists of 
female consumers willing to accept folate biofortified rice and having access to farmers in favor of 
this product. The high coverage rate  (81.91 %) also takes into account women that are indifferent 
to this product and access to farmers that are indifferent. The coverage rate is thus determined by 
the percentage of women that switch completely to folate biofortified rice, compared with a group 
of women that still consume traditional rice. The higher the coverage rate, the more NTDs that can 
be prevented by women’s consumption of biofortified rice. 
To determine the total folate intake after biofortification, additional knowledge of the current rice 
consumption pattern and folate intake is needed. According to China’s National Grain and Oils 
Information Center (CNGOIC, 2009), Shanxi Province has an average rice consumption of 157.8 g 
per person, per day in 2008, which is remarkably lower than the Chinese average of 315.29 g. 
Given this current rice consumption pattern and the average folate intake of biofortified rice, 
biofortification results in an average added folate intake of 460.7 µg per person, per day. The 
current folate intake level of women of childbearing age in Shanxi Province amounts 167.7 µg per 
day (Zhang et al., 2008). Adding the additional folate intake to this current daily folate intake, gives 
a total folate intake under biofortification of 637.4 µg per women of childbearing age, per day. 
Further, the “dose-response”, the effect of additionally absorbed folates on folate attributable NTDs, 
has to be assessed. Due to the lack of individual dietary intake data, the “dose” is based on the 
average folate intake in Shanxi Province under the biofortification scenario, around 640 µg per 
person, per day. This folate intake level is almost four times higher than the current intake level and, 
more important, exceeds the general accepted threshold to prevent folate deficiency and its adverse 
health effects, 400 µg per person, per day. Therefore, the “response” to biofortified folate intake is 
understood as the prevention of all NTDs caused by folate deficiency. Although Shanxi Province is 
mainly a wheat consuming region, with an annual rice consumption of only 58 kg per person, 
introducing rice with a folate content of approximately 1200 µg per 100 g rice would contribute to 
achieve the recommended daily folate intake of 400 µg per person in Shanxi Province. 
 
 
 
Results 
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The burden of folate deficiency in Shanxi Province, expressed in DALYs lost 
 
Based on the input parameters from Table 3, the DALY formula is used to calculate the current 
burden of folate deficiency in Shanxi Province. Table 4 presents this burden in terms of lost 
DALYs, for each contribution scenario. Based on consumption of traditional rice (i.e. without folate 
biofortified rice), the number of DALYs lost due to folate deficiency varies between 67 195 DALYs 
in the low and 94 073 DALYs in the high contribution scenario. The contribution of morbidity and 
mortality to the current burden amounts to 27.73 % and 72.27 %, respectively. The number of years 
lived with disability is the highest for spina bifida, while the lost life years are more or less equally 
divided between the two fatal functional outcomes. 
 
Table 4 Burden of folate deficiency in Shanxi Province, per functional outcome and contribution scenario, expressed in 
the number of DALYs lost 
Functional outcome 
Contribution of folate deficiency to NTDs            
     Lowa           Mediumb            Highc  
Morbidity    
Spina bifida 14 094 19 732 23 960 
Encephalocele   4 539 6 354 7 716 
Total (YLD) 18 633 26 086 31 676 
Mortality    
Stillbirths 23 434 32 808 39 838 
Abortions 25 128 35 179 42 718 
Total (YLL) 48 562 67 987 82 555 
Total (YLD + YLL) 67 195 94 073 114 232 
YLD, years lived in disability; YLL years of life lost 
a Low: 50 % of NTDs attributable to folate deficiency 
b Medium: 70 % of NTDs attributable to folate deficiency 
c High: 85 % of NTDs attributable to folate deficiency 
 
The health impact of folate biofortification of rice, expressed in DALYs saved 
 
The benefits of the introduction of folate biofortified rice in Shanxi Province is expressed as the 
number of DALYs gained through the intervention. This number is assessed by juxtaposing the 
number of DALYs lost under the current situation (“without”, see Table 4), and under a folate 
biofortification scenario (“with”, see Table 5).  
Taking into account the coverage rate and contribution of folate deficiency to NTDs, six impact 
scenario’s can be distinguished (Table 5). The average maternal folate intake after biofortification 
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in Shanxi Province saves between 24 830 DALYs in the “low-low” scenario and 93 569 DALYs in 
the “high-high” scenario (see Table 5). Due to a lower coverage rate and a diminished health effect, 
between 42 365 and 72 021 DALYs are still lost in the low impact scenario. These findings are 
based on the assumption that the average daily folate biofortified rice intake of 637.4 µg prevents 
women of having a baby with an NTD caused by folate deficiency. 
 
Table 5 Folate biofortification of rice in Shanxi Province, per functional outcome and contribution scenario, expressed 
in the number of DALYs saved per impact scenario 
Functional outcome 
  Low impact scenario       High impact scenario 
    Lowa Mediumb        Highc        Lowa       Mediumb               Highc 
Morbidity       
Spina bifida 5 208 7 291 8 854 11 545 16 163 19 626 
Encephalocele 1 677 2 348 2 851 3 718 5 205 6 320  
Total (YLD) 6 885 9 639 11 705 15 263 21 368 25 947 
Mortality       
Stillbirths 8 659 12 123 14 721 19 195 26 873 32 632 
Abortions 9 286 12 999 15 785 20 583 28 816 34 991 
Total (YLL) 17 945 25 122 30 506 39 778 55 689 67 623 
Total (YLD + YLL) 24 830 34 761 42 211 55 041 77 057 93 569 
YLD, years lived in disability; YLL years of life lost 
a Low contribution scenario: 50 % of NTDs attributable to folate deficiency 
b Medium contribution scenario: 70 % of NTDs attributable to folate deficiency 
c High contribution scenario: 85 % of NTDs attributable to folate deficiency 
 
 
Discussion 
 
The objective of this paper is to analyze ex-ante the health benefits of a folate biofortified rice 
intervention in a high NTD prevalence region. Although biofortified food products are still not 
produced, the commercialization of biofortified rice in China is more and more likely to happen. 
Recently, the Chinese Ministry of Agriculture (MOA) approved Bt rice as the first major biotech 
food crop, which is expected to be fully commercialized in two to three years (Shuping and Miles, 
2009). This illustrates China’s governmental support for research on biofortified rice using 
transgenic techniques (Fan et al., 2009; Pray and Huang, 2007). China’s support for rice 
biofortification is not surprising. China is not only the largest producer of conventional rice, but 
also a key player of genetically modified rice production (Jia et al., 2004; Wang and Johnston, 
2007). Therefore, China’s - and the world’s - most consumed staple crop, rice, will be probably 
preferred as the biofortified food product to tackle folate deficiency, which is not only a health 
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problem in Shanxi Province (Zhang et al., 2008), but also in China as a whole (De Steur et al., 
2010a; Zhao et al., 2009). Furthermore, folate biofortified rice is currently the most advanced folate 
biofortified staple crop (Blancquaert et al., 2008). Therefore, rather than using wheat, which is more 
consumed in Shanxi Province, our study on the health impact of folate biofortification focused on 
rice. Other folate biofortified products, such as lettuce (Nunes et al., 2009) and tomato (Diaz de la 
Garza et al., 2007) are less relevant to introduce in Shanxi Province, given the current dietary 
patterns. 
Although the use of the DALY approach to evaluate the health impact of biofortified crops has 
become popular, this method was subject to criticism (Allotey et al., 2003; Anand and Hanson, 
1998; Lyttkens, 2003). In this section the DALY framework as such is not discussed, but the data 
on which it is based. 
This paper compares the current burden of NTDs caused by folate deficiency with six 
biofortification scenarios. These scenarios are determined by the coverage rate of the folate 
enriched rice intervention and the importance of folate deficiency as a cause of NTDs. With respect 
to the latter, 50 % (‘low’), 70 % (‘medium’) and 80 % (‘high’) of the NTDs are assumed to be 
attributable to folate deficiency. If different contribution rates would be applied, such as the rate 
found in the Chinese study of Chen et al. (2008), 80 %, the size of the burden of folate deficiency 
will be directly influenced. Although our “high” contribution level is based on a study in Shanxi 
Province, we decided to include the general accepted range of contribution levels as alternative 
scenarios.  
The choice of these percentages reveals a lack of data on the specific non-linear relationship 
between dose and response. Therefore, the average daily folate intake under biofortification is 
considered as the dose, by which Shanxi women of childbearing age are protected from having a 
baby with an NTD caused by folate deficiency. This assumption is based on the difference between 
the average daily folate intake before (176.4 µg) and after (637.4 µg) the intervention and the 
contribution of the latter to the folate intake requirements, i.e. 159.4 %. Connecting individual 
consumption data with a non-linear dose-response function of folate intake and neural-tube defects 
would have provided a more realistic view on the health benefits of folate biofortification. 
However, such a dose-response function is not yet determined.  
Another limitation regarding the use of an average daily folate intake is the risk of extreme folic 
acid intake. A daily folic acid intake of 1 000 µg is set as an upper level which is safe for all 
populations. When exceeding this level, Vitamin B12 deficiency may be masked (Bailey, 2004; 
Bekaert et al., 2008). Although this is not traceable with the current data, this risk is less important 
in regions with a low intake of folic acid pills, such as Shanxi Province. Moreover, folate 
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biofortified rice mainly contains 5-methyl-tetrahydrofolate, a folate species known to have a much 
lesser effect on masking B12 deficiency (Storozhenko et al., 2007). 
Regarding the health impact of folate biofortification, the saved DALYs under the biofortification 
scenarios have to be understood as an estimated number. First, the health benefits only refer to the 
reduction of the number of NTDs as the main functional outcome of folate deficiency. If data on the 
contribution of folate deficiency to all its adverse health outcomes would be available, the total 
burden and the health benefits are expected to be much higher. Second, this health impact analysis 
would be more accurate if rice consumption data refers to women of childbearing age, instead of the 
total average in Shanxi Province. Therefore, primary data collection of female rice consumption 
patterns is required.  
Because most of the parameters used in the DALY framework are based on secondary data, 
sometimes referring to different years (e.g. NTD prevalence rate in 2003 and life expectancy in 
2006), additional research is needed to collect primary data. Furthermore, the impact of some of the 
efficacy parameters needs to be further explored, such as the bioavailability of folate biofortified 
rice. Another research topic is the cost-effectiveness of a folate biofortified intervention, which is 
assumed to be a pro-rural and pro-poor approach, and the comparison with other interventions to 
improve folate intake. On the one hand, increasing the consumption of folate rich products is less 
favorable in Shanxi Province, as it is hard to change dietary habits in a poor region. On the other 
hand, awareness and use of folic acid pills is still low in this province, with maternal intake levels of 
about 10 % (Li et al., 2007; Ren et al., 2006). Furthermore, because industrial folic acid fortification 
in grains requires appropriate infrastructure and quality control, it is less effective in poor Chinese 
regions (Campos-Bowers and Wittenmyer, 2007) as compared to developed countries (Cordero et 
al., 2008).  
If China would approve folate enriched rice as in the future, several policy issues should be 
addressed, such as labeling, intellectual property rights and trade or price policy issues (Campos-
Bowers and Wittenmyer, 2007). Furthermore, the implementation of folate biofortification 
programs should initially reach its target group, women of childbearing age from poor, rural areas. 
Also the procedures to commercialize the rice and distribute the seeds (through farmers or other 
channels; voluntary or mandatory) should be clarified and supported. And even if the Chinese 
policy would accept the production of biofortified staple crops, it should be taken into account that 
biofortification alone will only alleviate micronutrient malnutrition. A combination of interventions 
will be probably the most feasible and effective strategy to combat folate deficiency. 
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Conclusions 
 
This paper is an attempt to investigate the health benefits of a folate biofortified product in a 
specific region. In particular, it is an ex-ante evaluation of the health impact of folate enriched rice 
on folate deficiency in Shanxi Province, China. This region is characterized by one of the highest 
NTD prevalence rates in the world, partly due to its inadequate average folate intake level of 176.4 
µg per women, per day. While other interventions are less successful or practically less feasible in 
developing regions, like Shanxi Province, folate biofortified rice can be a valuable alternative to 
combat folate deficiency and its adverse health outcomes, such as NTDs. Application of Disability-
Adjusted Life Years approach shows that the introduction of folate biofortified rice would save 
between 24 830 and 42 211 DALYs in the low impact scenario and between 55 041 and 93 569 
DALYs in the high impact scenario. These findings are based on an estimated average folate intake 
after the introduction of biofortification, i.e. 637.4 µg per person, per day, which is significantly 
higher than the recommended intake of 400 µg to prevent the risk of having a baby with an NTD 
caused by folate deficiency.  
Although the DALY approach is a useful method to quantify the impact of folate biofortification on 
public health, the results are highly dependent on the value and the reliability of the parameters, in 
particular with respect to Shanxi Province. Primary data collection of the required parameters in 
Shanxi Province would give a more up-to-date picture of the burden and the potential health 
benefits. Nevertheless, these findings indicate that folate biofortification of rice has the potential to 
reduce the number of NTDs in high risk regions and should be considered as a potential alternative 
policy measure to further combat folate deficiency.  
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